News | May 14, 2025
GlaxoSmithKline Pharmaceuticals posts FY25 PAT at Rs. 915 Cr
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
This marks yet another milestone in our series of successful audits over the past year
The company has posted net profit of Rs. 55.36 crores for the Financial Year ended March 31, 2025
The change of name has been carried on pursuant to the Scheme of Amalgamation
Topiramate is indicated as a treatment of epilepsy and migraine
The company has posted net profit of Rs. 582.01 crores for the Financial Year ended March 31, 2025
This significant milestone enhances our global regulatory standing
Alembic Pharmaceuticals commissions new facility at Pithampur
This approval authorizes the company to export Ibuprofen to the Chinese markets
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Subscribe To Our Newsletter & Stay Updated
